Sequenom May Report Down Syndrome Trial Results
August 31, 2009 at 17:10 PM EDT
Speculation that Sequenom Inc. (Nasdaq: SQNM) may report positive test results for its prenatal Down Syndrome test lifted shares of the genetic analysis products maker $1.11 to close at $6.39.
